
Best Agrolife Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- The company targets a 30% revenue growth for FY24, building on a 40% growth in FY23.
- FY24 top-line is expected around Rs. 2,300 crores with an EBITDA margin of 20%.
- Volume growth will contribute alongside price impact, despite downward pressure on raw material prices.
- Q1 and Q2 of FY24 are expected to show stronger growth compared to the rest of the year.
- New product launches (e.g., Pyroxasulfone) and aggressive sales preparation support growth.
- The company aims to shift from generics (~20% currently) to specialized/patented molecules by FY25.
- Export plans will start from FY24, adding to growth opportunities.
- Growth drivers include new product portfolio, branded products, and expanded market presence domestically and internationally.
- Confidence expressed in achieving these targets despite pricing pressures and cyclicality in agriculture sector.
See what Best Agrolife management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company plans around Rs. 200 crores CAPEX mostly in FY24 with some spillover to FY25, primarily funded through long-term bank loans.
- Bankers are supportive and ready to provide term loans; there is no issue in accessing debt funding.
- The company currently has minimal long-term debt and maintains a healthy debt-to-equity ratio.
- Management is also open to equity fundraising, though no firm plans or timelines were specified.
- Debt increase recently is primarily for working capital support, considered temporary, with efforts underway to reduce working capital pressure.
- Overall, CAPEX funding is sorted predominantly via debt, with equity raise being a potential but not definite option.
See what Best Agrolife management said on order book — free account, 30 seconds.
Capex plans
Yes- Best Agrolife Limited has planned a capital expenditure (CAPEX) of Rs. 200 crores.
- Most of this CAPEX is expected to be completed in FY24, with some spillover into FY25.
- The CAPEX is focused on capacity enhancement and backward integration.
- Funding for CAPEX is well-supported by bankers with long-term borrowing options available; the company has minimal long-term debt.
- The management is evaluating both debt and equity routes for CAPEX funding but bankers are committed to support via term loans.
- The strategic focus includes moving towards specialized and patented molecules, including the launch of a new patented herbicide.
- The company aims to reduce working capital pressure and improve cash conversion cycle in FY24, expecting visible positive results by Q2 FY24.
Track Best Agrolife — get its next earnings analysis in your feed
How does Best Agrolife rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does Best Agrolife rank in Fertilizers & Agrochemicals?
Compare Best Agrolife against every Fertilizers & Agrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Best Agrolife's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Madhya Bharat Agro Products (Q2 FY27)
Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo
- Dhansa Labs (Q2 FY27)
1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aristo Bio-Tech (Q2 FY27)
1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu
- Krishana Phoschem (Q2 FY27)
Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres